Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$4.14
-0.3%
$2.87
$1.60
$15.04
$112.06M1.84257,142 shs78,670 shs
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
$2.31
+2.7%
$2.16
$1.15
$33.98
$111.60M-2.051.40 million shs633,964 shs
TAOX
Synaptogenix
$6.92
-0.6%
$0.00
$1.84
$11.98
$24.13M1.87425,116 shs198,735 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.87
-1.1%
$1.70
$1.02
$6.23
$106.12M0.99458,840 shs115,250 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
+5.22%+19.68%+34.25%+51.74%-64.45%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
+4.17%+2.74%-4.26%+7.14%-92.44%
TAOX
Synaptogenix
-0.71%0.00%-17.24%+695,999,900.00%+695,999,900.00%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-0.53%+12.50%-2.07%+30.34%-66.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
1.8832 of 5 stars
3.31.00.00.01.10.01.3
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
1.9553 of 5 stars
1.01.00.04.72.20.80.6
TAOX
Synaptogenix
N/AN/AN/AN/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.0988 of 5 stars
3.55.00.00.01.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2.57
Moderate Buy$8.50105.41% Upside
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.00
Hold$2.00-13.42% Downside
TAOX
Synaptogenix
0.00
N/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$7.80317.11% Upside

Current Analyst Ratings Breakdown

Latest TAOX, SAVA, TCRX, and ANRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
8/12/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
6/26/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/A$4.56 per shareN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/A$1.82 per shareN/A
TAOX
Synaptogenix
$3.96K6,090.37N/AN/A$4.95 per share1.40
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$2.82M37.63N/AN/A$3.11 per share0.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$61.43M-$2.39N/AN/AN/AN/A-44.34%-36.73%11/11/2025 (Estimated)
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$24.34M-$2.55N/AN/AN/AN/A-66.16%-53.11%11/13/2025 (Estimated)
TAOX
Synaptogenix
-$12.77M-$20.16N/AN/AN/A-277.76%-150.79%N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$127.50M-$1.09N/AN/AN/A-1,964.88%-63.33%-40.19%11/11/2025 (Estimated)

Latest TAOX, SAVA, TCRX, and ANRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2025Q2 2025
TAOX
Synaptogenix
N/A-$11.26N/A-$11.26N/AN/A
8/14/2025Q2 2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A-$0.18N/A-$0.92N/AN/A
8/13/2025Q2 2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.57-$0.65-$0.08-$0.65N/AN/A
8/12/2025Q2 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.2848-$0.0048-$0.28$1.31 million$3.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/AN/A
TAOX
Synaptogenix
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.18
18.43
18.43
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A
2.43
2.43
TAOX
Synaptogenix
N/A
20.52
20.52
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.18
7.06
7.06

Institutional Ownership

CompanyInstitutional Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
38.05%
TAOX
Synaptogenix
10.34%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
12.20%
TAOX
Synaptogenix
2.73%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
4.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A27.08 millionN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3048.31 million42.41 millionOptionable
TAOX
Synaptogenix
43.49 million3.39 millionN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.75 million54.28 millionNot Optionable

Recent News About These Companies

Lifesci Capital Issues Pessimistic Outlook for TCRX Earnings
Wedbush Cuts Earnings Estimates for TScan Therapeutics
HC Wainwright Expects Higher Earnings for TScan Therapeutics
Q3 EPS Estimates for TScan Therapeutics Cut by Wedbush
Research Analysts Set Expectations for TCRX Q3 Earnings
TScan Therapeutics Elects New Directors at Annual Meeting

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alto Neuroscience stock logo

Alto Neuroscience NYSE:ANRO

$4.14 -0.01 (-0.29%)
Closing price 03:59 PM Eastern
Extended Trading
$4.13 -0.01 (-0.19%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Cassava Sciences stock logo

Cassava Sciences NASDAQ:SAVA

$2.31 +0.06 (+2.67%)
Closing price 04:00 PM Eastern
Extended Trading
$2.31 0.00 (-0.22%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Synaptogenix NASDAQ:TAOX

$6.92 -0.04 (-0.57%)
As of 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.87 -0.02 (-1.06%)
Closing price 04:00 PM Eastern
Extended Trading
$1.88 +0.01 (+0.53%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.